Here are five trends:
1. The market is expected to grow at a compound annual growth rate of 8.3 percent.
2. It is projected to reach a value of $87.2 million in 2022.
3. The demand for platelet rich plasma therapy is expected to increase due to awareness of the multiple advantages of PRP therapy. Another key growth factor is the growing geriatric population in need of surgeries and treatments.
4. In 2013, the orthopedic application segment held 38 percent of the market for PRP therapy in Europe.
5. In 2013, EmCyte, Arthrex and Biomet dominated the market.
More articles on devices:
17 new device launches & releases — October 26, 2015
25 spine devices receive FDA 510(k) clearances in September
Asia Pacific to see greatest growth in minimally invasive neurosurgery devices market: 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
